STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.

News Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Equities

300204

CNE100001237

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
6.68 ^CNY	+3.09%		+6.03%	-34.25%

Apr. 24	Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 25	Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index	23-09-18	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Staidson BioPharmaceuticals Co., Ltd. amended terms of the transaction	23-06-25	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18%	23-04-06	MT
Review Into Staidson Biopharma Unit's Anti-COVID-19 Drug Shows Safety, Tolerability in Patients; Shares Jump 5%	23-02-17	MT
Staidson's Respiratory Drug Shows Safety in Trial	23-01-23	MT
Chinese Shares Finish Lower; Staidson Falls 8% After Signing R&D Deal With Germany’s InflaRx	22-12-23	MT
Staidson Forms R&D Deal With Germany’s InflaRx	22-12-22	MT
Staidson BioPharmaceuticals Co., Ltd. announced that it expects to receive CNY 580 million in funding	22-12-21	CI
Inflarx Gmbh and Staidson Biopharmaceuticals Co., Ltd Enters into Third Addendum to the Co-Development Agreement	22-12-21	CI
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19	22-12-21	AQ
InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson BioPharmaceuticals Co., Ltd.	22-12-20	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-18	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Equities

300204

CNE100001237

Summary

Filters